Biotech Analysis

Cytokinetics’ Cardio Bet Pays Off with Amgen Option Exercise
Cytokinetics Inc.’s decision to scrap its internal oncology programs and focus on heart failure drug CK-1827452 is looking pretty smart now that partner Amgen Inc. exercised its option on the drug, triggering a $50 million payment to Cytokinetics. Amgen will cover all future expenses, including two [...]

Genentech Deal Looking Better; Avastin Misses in First Adjuvant Trial
Though some analysts believed Genentech Inc. could have gotten more than $95 per share for its remaining minority stake in the $46.8 billion deal with Roche Holdings AG earlier this year, the buyout price was looking pretty good Wednesday, after Genentech reported that cancer drug Avastin [...]